Cellular and T cell engager Immunotherapy

P-001: The bone marrow stroma influences extrinsic apoptotic signaling and results in resistance to BCMA CAR-T cell induced cell death

P-002: Impact of Bridging Therapy (BT) on outcome of Relapsed Refractory Multiple Myeloma (RRMM) with Ide-cel CAR T-cell therapy: Real-world Experience from the U.S. Myeloma CAR T Consortium

P-003: Clinical outcomes among multiple myeloma and lymphoma patients taking beta-blockers undergoing CAR-T therapy

P-004: Expansion, persistence, and characteristics of autologous, BHV-1100 ARMored memory-like NK cells infused prior to autologous stem cell transplant in MRD+, newly diagnosed multiple myeloma patients

P-005: Association of baseline soluble BCMA with measures of disease burden and response to linvoseltamab: a comprehensive analysis in patients with relapsed/refractory multiple myeloma (RRMM)

P-006: sBCMA has utility for early response monitoring in the blood and is correlated with forimtamig pharmacodynamic activity, clinical response and MRD

P-007: Prognostic Impact of Corticosteroid and Tocilizumab Use on the Efficacy of Chimeric Antigen Receptor T-cell Therapy for Relapsed/Refractory Multiple Myeloma

P-008: Idecabtagene vicleucel (ide-cel) vs standard regimens in triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis in patients receiving bridging therapy

P-009: Cellular dynamics following CAR T cell therapy are associated with response, resistance and cytokine release syndrome in relapsed/refractory myeloma

P-010: Tumor-intrinsic features associated with progression-free survival (PFS) in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel)

P-011: Hematopoietic reconstitution and infections after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma are associated with pre-CAR-T bridging therapies

P-012: Safety and Efficacy of Standard of Care (SOC) Teclistamab (TEC) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM), a single center experience

P-013: Patterns of Cytokine Release Syndrome with Teclistamab in Relapsed/Refractory Multiple Myeloma with or without Prior T-Cell Redirection Therapy.

P-014: TECLISTAMAB IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA: PATIENTS CHARACTERISTICS FROM POST MARKETING ACCES (ACCES PRECOCE) IN FRANCE

P-015: A Novel CAR-T cell therapy targeting kappa myeloma antigen for the treatment of multiple myeloma

P-016: DISPARITIES IN ACCESS AND PRACTICE PATTERNS OF BCMA-DIRECTED T-CELL ENGAGER (TCE) THERAPIES IN MULTIPLE MYELOMA: A GLOBAL PERSPECTIVE

P-017: Real-World Efficacy of CAR T-Cell Therapies: A HealthTree Cure Hub’s Study of Multiple Myeloma Patients

P-018: Prior BCMA-directed bispecific antibody or CAR T is not associated with increased risk of early infections in patients treated with bispecific antibodies.

P-019: Novel combination immunotherapy for relapsed/refractory multiple myeloma (RRMM): initial Phase 1 safety run-in results for cevostamab in combination with pomalidomide and dexamethasone

P-020: Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance following Autologous Hematopoietic Cell Transplant (HCT) results in long-term sustained T cell activation and clonotypic expansion

P-021: Durable response to CAR T cell treatment is associated with the downstream triggering of native T cell immunity: a lesson learned from B cell lymphoma patients

P-022: DEVELOPMENT OF TROGOCYTOSIS RESISTANT CAR-NK FOR MULTIPLE MYELOMA

P-023: Talquetamab, a G Protein–Coupled Receptor Family C Group 5 Member D × CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma: Efficacy and Safety of Patient Subgroups from MonumenTAL-1

P-024: Early outcomes and therapy modification strategies in Multiple Myeloma patients treated with teclistamab, CD3XBCMA BITE; a single center experience.

P-025: Synergistic antitumor activity of the BCMA 2+1 T-cell engager (TCE) alnuctamab (ALNUC; BMS-986349; CC-93269) and CELMoD agents in multiple myeloma (MM) preclinical models

P-026: Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma

P-027: Hotspot mutations in BCMA extracellular domain lead to differential susceptibility to anti-BCMA targeted immunotherapies

P-028: Canadian-made single domain antibody (sdAb) BCMA CAR-T cells for Multiple Myeloma

P-029: Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma

P-030: First Results From the RedirecTT-1 Study With Teclistamab (tec) + Talquetamab (tal) Simultaneously Targeting BCMA and GPRC5D in Patients (pts) With Relapsed/Refractory Multiple Myeloma (RRMM)

P-031: Idecabtagene vicleucel (ide-cel) vs standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 subgroup analysis by prior lines of therapy

P-032: Ide-cel versus standard regimens in patients with triple-class–exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 analysis in the modified intention to-treat (mITT) population

P-033: Real World Evaluation of Teclistamab in Patients with RRMM: Results from the IMF Immunotherapy Database Project

P-034: Alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA × CD3 T-cell engager, in patients (pts) with relapsed/refractory multiple myeloma (RRMM): latest results from a phase 1 first-in-human clinical study

P-036: REAL WORLD SINGLE CENTER EXPERIENCE OF LONG-TERM TOXICITIES WITH ANTI-BCMA CAR T-CELL THERAPY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

P-037: BMS-986393 (CC-95266), a G protein-coupled receptor class C group 5 member D (GPRC5D)-targeted CAR T-cell therapy for relapsed/refractory multiple myeloma (RRMM): results from a phase 1 study

P-038: Impact of Absolute Lymphocyte Count at pre-apheresis and pre-lymphodepletion on Chimeric Antigen Receptor (CAR)-T Therapy Outcomes in Relapsed Refractory Multiple Myeloma (RRMM)

P-039: Vitamin D Deficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

P-040: Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): a KarMMa-3 high-risk subgroup analysis

P-041: Efficacy and safety of BCMA-specific CAR T cell-based therapy in relapsed/refractory multiple myeloma patients with extramedullary disease

P-042: Early infections in myeloma patients treated with anti-BCMA bispecific antibodies.

P-043: Leveraging wearable devices for remote patient monitoring facilitate earlier CRS detection following CAR-T therapy in relapsed/refractory multiple myeloma (RRMM): Early results from an IIT

P-044: Evaluation of the efficacy and safety of two different linvoseltamab Phase 2 dose regimens: Results from LINKER-MM1

P-045: Early Treatment With Bispecific T-cell Redirectors (Teclistamab or Talquetamab) + Daratumumab in Newly Diagnosed High-risk Multiple Myeloma: An Open-label, Phase 2, Pilot Study (GEM-TECTAL)

P-046: Trial in Progress: Linvoseltamab, a BCMAxCD3 bispecific antibody, in a Phase 1b multi-cohort study of combination regimens for patients with relapsed/refractory multiple myeloma

P-047: TRIAL IN PROGRESS: AN OPEN-LABEL, MULTICENTER, PHASE 1 STUDY OF IGM-2644 IN PARTICIPANTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA (RRMM)

P-048: POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS MOSTLY WITH HIGH-RISK DISEASE FEATURES

P-049: Safety and Efficacy of Standard of Care Ciltacabtagene Autoleucel (Cilta-cel) for Relapsed/Refractory Multiple Myeloma (RRMM): Real World Experience

P-050: GEN3014 (HexaBody®-CD38) Versus Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma: Design of Randomized Head-to-Head Expansion Cohort of Phase 1/2 Trial

P-051: Safety and efficacy of chimeric antigen receptor T cell therapy in patients with relapse or refractory multiple myeloma and hepatitis B virus-infection

P-052: LINKER-MM3, a Phase 3, Open-Label, Randomized Study of Linvoseltamab Versus Elotuzumab, Pomalidomide, and Dexamethasone (EPd) in Relapsed/Refractory Multiple Myeloma (RRMM)

P-053: Idecabtagene vicleucel (ide-cel) retreatment response was characterized by poor activation, impaired cellular expansion, and limited cytolytic activity of chimeric antigen receptor (CAR) T cells

P-493: Bispecific CS1-BCMA CAR-T cells are clinically active in relapsed or refractory multiple myeloma: an updated clinical study

P-509: Vactosertib, a novel TGF type I receptor kinase inhibitor, improves T-cell fitness:a single-arm, phase 1b trial in relapsed/refractory multiple myeloma